- Home
- OIO vs TLSA Comparison
OIO vs TLSA Comparison
Compare OIO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIO | TLSA |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Cayman Islands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 155.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | OIO | TLSA |
|---|---|---|
| Price | $2.06 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.0K | ★ 199.2K |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.99 |
| 52 Week High | $7.50 | $2.60 |
Technical Indicators
Market Signals| Indicator | OIO | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 33.58 |
| Support Level | $1.65 | N/A |
| Resistance Level | $2.55 | $1.45 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 52.23 | 7.08 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.